Proactive Investors - Run By Investors For Investors

ANGLE device has lymph node potential, says German research team

"This is another example of our leveraged approach with research customers delivering new applications for Parsortix,” said ANGLE chief executive Andrew Newland
ANGLE  device has lymph node potential, says German research team
Dr Bernhard Polzer and his team at the Fraunhofer Institute for Toxicology and Experimental Medicine provided a glowing recommendation of the device

ANGLE PLC’s (LON:AGL) shares rose on Friday as the firm revealed it has found a potential new application for its liquid biopsy.

Dr Bernhard Polzer and his team at the Fraunhofer Institute for Toxicology and Experimental Medicine, in Regensburg, Germany, found ANGLE’s Parsortix system streamlines the analysis of lymph nodes in melanoma.

WATCH: ANGLE's Parsortix device plays critical role in ground-breaking new cancer research

Not only that, the new process incorporating Parsortix is more sensitive to detecting the spread of the disease to the lymph node, “greatly improving the ability to undertake key molecular analysis on cancer”. 

“It is an added benefit that it also facilitates single cell analysis reducing costs,” said Polzer.

“We previously tried other CTC [circulating tumour cell] systems including antibody-based and membrane systems but these were not suitable for this process."

Polzer’s research has been published as a peer-reviewed publication in the International Journal of Cancer.

"This is another example of our leveraged approach with research customers delivering new applications for Parsortix,” said ANGLE chief executive Andrew Newland.

“There is now the potential for the Parsortix system to be adopted as a standard approach for analysing lymph nodes, which is a requirement for all patients diagnosed with melanoma and several other cancer types."

In late morning trading, shares in ANGLE were 8.2% higher at 59.50p.

 -- Adds share price --

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use